

ASX ANNOUNCEMENT

DESPATCH OF OFFER BOOKLET AND ENTITLEMENT AND ACCEPTANCE FORM

Wellington, NZ, 11th June 2019: Volpara Health Technologies Limited ("**Volpara**"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, announces that it has today despatched its retail entitlement offer booklet and personalised entitlement and acceptance form to eligible retail shareholders (**Offer Booklet**).

The Offer Booklet, a copy of which was released on ASX on Wednesday, 5 June 2019, contains information for eligible retail shareholders in relation to Volpara's fully underwritten pro rata accelerated non-renounceable entitlement offer announced on Monday, 3 June 2019 (**Entitlement Offer**). The Entitlement Offer is being undertaken by Volpara as part of a broader \$55 million capital raise to fund the purchase price under a merger agreement to acquire 100% of the issued share capital of US-based MRS Systems, Inc. (**MRS**) (the **Acquisition**) (together with associated costs) and to fund further organic growth. As previously announced the Entitlement Offer is being undertaken alongside an institutional placement of new shares in Volpara that raised A\$45 million (**Placement**). The Placement is due to settle tomorrow, 12 June 2019.

Only eligible retail shareholders in Australia and New Zealand may participate in the Entitlement Offer. The eligibility criteria for the Entitlement Offer are set out in the Offer Booklet. Ineligible shareholders will be notified separately of their inability to participate.

The Entitlement Offer will close at **5.00pm (Sydney time) on Wednesday, 26 June 2019**, unless extended. Eligible retail shareholders who wish to participate in the Entitlement Offer are encouraged to complete and return their personalised entitlement and acceptance form as soon as possible by one of the methods set out in the Offer Booklet.

For further information on, or if you have any questions in respect of, the Retail Entitlement Offer, you may call the Volpara Offer Information Line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) Monday to Friday from 8.30 am to 5.30 pm (Sydney time), during the offer period.

ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, provides role specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

For more information, visit www.volparasolutions.com.

IMPORTANT NOTICE

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction. Any shares issued to eligible retail shareholders under the Entitlement Offer have not been, and will not be registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act of 1933 and any applicable US state securities laws.

The Information in this announcement is of general background and does not purport to be complete. It should be read in conjunction with Volpara's other periodic and continuous disclosure announcements lodged with ASX Limited, which are available at www.asx.com.au. You are advised to read these Important Notices carefully before reading or making any other use of this announcement or any information contained in this announcement. In accepting this announcement, you agree to be bound by these terms and conditions, including any modifications to them.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES